APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hypertension Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hypertension Drug Market Analysis and Forecast 2026-2032

22 December 2025210 pages

Choose your research edition.

Industry ResearchHypertension Drug Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Hypertension Drug Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Hypertension Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hypertension Drug Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Hypertension Drug Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Hypertension Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hypertension Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hypertension Drug include Actelion Ltd., Alvogen, Bellerophon Therapeutics, Inc, Boehringer Ingelheim, Boryung Pharmaceutical Co.,Ltd, Bristol-Myers Squibb and Company,, Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hypertension Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hypertension Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Hypertension Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hypertension Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hypertension Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hypertension Drug sales, projected growth trends, production technology, application and end-user industry.

Hypertension Drug Segment by Company

Actelion Ltd.

Alvogen

Bellerophon Therapeutics, Inc

Boehringer Ingelheim

Boryung Pharmaceutical Co.,Ltd

Bristol-Myers Squibb and Company,

Daiichi Sankyo Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc

HanAll Biopharma Co., Ltd

Hanmi Pharmaceutical Co., Ltd

JW Pharmaceutical Corporation (Choongwae Pharma)

Kyowa Kirin Co., Ltd

Lung Biotechnology PBC

Lupin Limited

Nippon Shinyaku Co. Ltd

Noden Pharma DAC

Ranbaxy Laboratories Limited

AstraZeneca Plc

Bayer AG

Pfizer Inc

Eli Lilly and Company

Merck & Co.

Novartis AG

Novartis AG

Johnson & Johnson Ltd

Sanofi S.A

Hypertension Drug Segment by Type

Beta Blockers Vasodilators

Alpha Blockers

Calcium Channel Blockers

Diuretics

Renin Inhibitors

Angiotensin Receptor Blockers

Angiotensin Converting Enzyme Inhibitors

Hypertension Drug Segment by Application

Hospitals

Clinics

Others

Hypertension Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypertension Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hypertension Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hypertension Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hypertension Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hypertension Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Beta Blockers Vasodilators Major Manufacturers Table 3. Alpha Blockers Major Manufacturers Table 4. Calcium Channel Blockers Major Manufacturers Table 5. Diuretics Major Manufacturers Table 6. Renin Inhibitors Major Manufacturers Table 7. Angiotensin Receptor Blockers Major Manufacturers Table 8. Angiotensin Converting Enzyme Inhibitors Major Manufacturers Table 9. Global Hypertension Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Hospitals Major Manufacturers Table 11. Clinics Major Manufacturers Table 12. Others Major Manufacturers Table 13. Hypertension Drug Industry Trends Table 14. Hypertension Drug Industry Drivers Table 15. Hypertension Drug Industry Opportunities and Challenges Table 16. Hypertension Drug Industry Restraints Table 17. Global Hypertension Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Hypertension Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Hypertension Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Hypertension Drug Revenue Market Share by Region (2021-2026) Table 21. Global Hypertension Drug Revenue Market Share by Region (2027-2032) Table 22. Global Hypertension Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Hypertension Drug Sales by Region (2021-2026) & (k units) Table 24. Global Hypertension Drug Sales by Region (2027-2032) & (k units) Table 25. Global Hypertension Drug Sales Market Share by Region (2021-2026) Table 26. Global Hypertension Drug Sales Market Share by Region (2027-2032) Table 27. Global Hypertension Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Hypertension Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Hypertension Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Hypertension Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Hypertension Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Hypertension Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Hypertension Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Hypertension Drug Manufacturers, Product Type & Application Table 35. Global Hypertension Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Hypertension Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Hypertension Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Hypertension Drug Revenue Market Share by Type (2021-2026) Table 42. Global Hypertension Drug Revenue Market Share by Type (2027-2032) Table 43. Global Hypertension Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Hypertension Drug Sales by Type (2021-2026) & (k units) Table 45. Global Hypertension Drug Sales by Type (2027-2032) & (k units) Table 46. Global Hypertension Drug Sales Market Share by Type (2021-2026) Table 47. Global Hypertension Drug Sales Market Share by Type (2027-2032) Table 48. Global Hypertension Drug Price by Type (2021-2026) & (US$/unit) Table 49. Global Hypertension Drug Price by Type (2027-2032) & (US$/unit) Table 50. Global Hypertension Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Hypertension Drug Revenue Market Share by Application (2021-2026) Table 54. Global Hypertension Drug Revenue Market Share by Application (2027-2032) Table 55. Global Hypertension Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Hypertension Drug Sales by Application (2021-2026) & (k units) Table 57. Global Hypertension Drug Sales by Application (2027-2032) & (k units) Table 58. Global Hypertension Drug Sales Market Share by Application (2021-2026) Table 59. Global Hypertension Drug Sales Market Share by Application (2027-2032) Table 60. Global Hypertension Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Hypertension Drug Price by Application (2027-2032) & (US$/unit) Table 62. Actelion Ltd. Company Information Table 63. Actelion Ltd. Business Overview Table 64. Actelion Ltd. Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Actelion Ltd. Hypertension Drug Product Portfolio Table 66. Actelion Ltd. Recent Development Table 67. Alvogen Company Information Table 68. Alvogen Business Overview Table 69. Alvogen Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Alvogen Hypertension Drug Product Portfolio Table 71. Alvogen Recent Development Table 72. Bellerophon Therapeutics, Inc Company Information Table 73. Bellerophon Therapeutics, Inc Business Overview Table 74. Bellerophon Therapeutics, Inc Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Bellerophon Therapeutics, Inc Hypertension Drug Product Portfolio Table 76. Bellerophon Therapeutics, Inc Recent Development Table 77. Boehringer Ingelheim Company Information Table 78. Boehringer Ingelheim Business Overview Table 79. Boehringer Ingelheim Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Boehringer Ingelheim Hypertension Drug Product Portfolio Table 81. Boehringer Ingelheim Recent Development Table 82. Boryung Pharmaceutical Co.,Ltd Company Information Table 83. Boryung Pharmaceutical Co.,Ltd Business Overview Table 84. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product Portfolio Table 86. Boryung Pharmaceutical Co.,Ltd Recent Development Table 87. Bristol-Myers Squibb and Company, Company Information Table 88. Bristol-Myers Squibb and Company, Business Overview Table 89. Bristol-Myers Squibb and Company, Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb and Company, Hypertension Drug Product Portfolio Table 91. Bristol-Myers Squibb and Company, Recent Development Table 92. Daiichi Sankyo Company Company Information Table 93. Daiichi Sankyo Company Business Overview Table 94. Daiichi Sankyo Company Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo Company Hypertension Drug Product Portfolio Table 96. Daiichi Sankyo Company Recent Development Table 97. F. Hoffmann-La Roche Ltd. Company Information Table 98. F. Hoffmann-La Roche Ltd. Business Overview Table 99. F. Hoffmann-La Roche Ltd. Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. F. Hoffmann-La Roche Ltd. Hypertension Drug Product Portfolio Table 101. F. Hoffmann-La Roche Ltd. Recent Development Table 102. Gilead Sciences, Inc Company Information Table 103. Gilead Sciences, Inc Business Overview Table 104. Gilead Sciences, Inc Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Gilead Sciences, Inc Hypertension Drug Product Portfolio Table 106. Gilead Sciences, Inc Recent Development Table 107. HanAll Biopharma Co., Ltd Company Information Table 108. HanAll Biopharma Co., Ltd Business Overview Table 109. HanAll Biopharma Co., Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. HanAll Biopharma Co., Ltd Hypertension Drug Product Portfolio Table 111. HanAll Biopharma Co., Ltd Recent Development Table 112. Hanmi Pharmaceutical Co., Ltd Company Information Table 113. Hanmi Pharmaceutical Co., Ltd Business Overview Table 114. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product Portfolio Table 116. Hanmi Pharmaceutical Co., Ltd Recent Development Table 117. JW Pharmaceutical Corporation (Choongwae Pharma) Company Information Table 118. JW Pharmaceutical Corporation (Choongwae Pharma) Business Overview Table 119. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product Portfolio Table 121. JW Pharmaceutical Corporation (Choongwae Pharma) Recent Development Table 122. Kyowa Kirin Co., Ltd Company Information Table 123. Kyowa Kirin Co., Ltd Business Overview Table 124. Kyowa Kirin Co., Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Kyowa Kirin Co., Ltd Hypertension Drug Product Portfolio Table 126. Kyowa Kirin Co., Ltd Recent Development Table 127. Lung Biotechnology PBC Company Information Table 128. Lung Biotechnology PBC Business Overview Table 129. Lung Biotechnology PBC Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Lung Biotechnology PBC Hypertension Drug Product Portfolio Table 131. Lung Biotechnology PBC Recent Development Table 132. Lupin Limited Company Information Table 133. Lupin Limited Business Overview Table 134. Lupin Limited Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Lupin Limited Hypertension Drug Product Portfolio Table 136. Lupin Limited Recent Development Table 137. Nippon Shinyaku Co. Ltd Company Information Table 138. Nippon Shinyaku Co. Ltd Business Overview Table 139. Nippon Shinyaku Co. Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. Nippon Shinyaku Co. Ltd Hypertension Drug Product Portfolio Table 141. Nippon Shinyaku Co. Ltd Recent Development Table 142. Noden Pharma DAC Company Information Table 143. Noden Pharma DAC Business Overview Table 144. Noden Pharma DAC Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Noden Pharma DAC Hypertension Drug Product Portfolio Table 146. Noden Pharma DAC Recent Development Table 147. Ranbaxy Laboratories Limited Company Information Table 148. Ranbaxy Laboratories Limited Business Overview Table 149. Ranbaxy Laboratories Limited Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 150. Ranbaxy Laboratories Limited Hypertension Drug Product Portfolio Table 151. Ranbaxy Laboratories Limited Recent Development Table 152. AstraZeneca Plc Company Information Table 153. AstraZeneca Plc Business Overview Table 154. AstraZeneca Plc Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 155. AstraZeneca Plc Hypertension Drug Product Portfolio Table 156. AstraZeneca Plc Recent Development Table 157. Bayer AG Company Information Table 158. Bayer AG Business Overview Table 159. Bayer AG Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 160. Bayer AG Hypertension Drug Product Portfolio Table 161. Bayer AG Recent Development Table 162. Pfizer Inc Company Information Table 163. Pfizer Inc Business Overview Table 164. Pfizer Inc Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 165. Pfizer Inc Hypertension Drug Product Portfolio Table 166. Pfizer Inc Recent Development Table 167. Eli Lilly and Company Company Information Table 168. Eli Lilly and Company Business Overview Table 169. Eli Lilly and Company Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 170. Eli Lilly and Company Hypertension Drug Product Portfolio Table 171. Eli Lilly and Company Recent Development Table 172. Merck & Co. Company Information Table 173. Merck & Co. Business Overview Table 174. Merck & Co. Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 175. Merck & Co. Hypertension Drug Product Portfolio Table 176. Merck & Co. Recent Development Table 177. Novartis AG Company Information Table 178. Novartis AG Business Overview Table 179. Novartis AG Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 180. Novartis AG Hypertension Drug Product Portfolio Table 181. Novartis AG Recent Development Table 182. Novartis AG Company Information Table 183. Novartis AG Business Overview Table 184. Novartis AG Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 185. Novartis AG Hypertension Drug Product Portfolio Table 186. Novartis AG Recent Development Table 187. Johnson & Johnson Ltd Company Information Table 188. Johnson & Johnson Ltd Business Overview Table 189. Johnson & Johnson Ltd Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 190. Johnson & Johnson Ltd Hypertension Drug Product Portfolio Table 191. Johnson & Johnson Ltd Recent Development Table 192. Sanofi S.A Company Information Table 193. Sanofi S.A Business Overview Table 194. Sanofi S.A Hypertension Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 195. Sanofi S.A Hypertension Drug Product Portfolio Table 196. Sanofi S.A Recent Development Table 197. North America Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 198. North America Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 199. North America Hypertension Drug Sales by Type (2021-2026) & (k units) Table 200. North America Hypertension Drug Sales by Type (2027-2032) & (k units) Table 201. North America Hypertension Drug Sales Price by Type (2021-2026) & (US$/unit) Table 202. North America Hypertension Drug Sales Price by Type (2027-2032) & (US$/unit) Table 203. North America Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 204. North America Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 205. North America Hypertension Drug Sales by Application (2021-2026) & (k units) Table 206. North America Hypertension Drug Sales by Application (2027-2032) & (k units) Table 207. North America Hypertension Drug Sales Price by Application (2021-2026) & (US$/unit) Table 208. North America Hypertension Drug Sales Price by Application (2027-2032) & (US$/unit) Table 209. North America Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 210. North America Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 211. North America Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 212. North America Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 213. North America Hypertension Drug Sales by Country (2021-2026) & (k units) Table 214. North America Hypertension Drug Sales by Country (2027-2032) & (k units) Table 215. North America Hypertension Drug Sales Price by Country (2021-2026) & (US$/unit) Table 216. North America Hypertension Drug Sales Price by Country (2027-2032) & (US$/unit) Table 217. United States Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 218. Canada Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 219. Mexico Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 220. Europe Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 221. Europe Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 222. Europe Hypertension Drug Sales by Type (2021-2026) & (k units) Table 223. Europe Hypertension Drug Sales by Type (2027-2032) & (k units) Table 224. Europe Hypertension Drug Sales Price by Type (2021-2026) & (US$/unit) Table 225. Europe Hypertension Drug Sales Price by Type (2027-2032) & (US$/unit) Table 226. Europe Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 227. Europe Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 228. Europe Hypertension Drug Sales by Application (2021-2026) & (k units) Table 229. Europe Hypertension Drug Sales by Application (2027-2032) & (k units) Table 230. Europe Hypertension Drug Sales Price by Application (2021-2026) & (US$/unit) Table 231. Europe Hypertension Drug Sales Price by Application (2027-2032) & (US$/unit) Table 232. Europe Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. Europe Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. Europe Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. Europe Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 236. Europe Hypertension Drug Sales by Country (2021-2026) & (k units) Table 237. Europe Hypertension Drug Sales by Country (2027-2032) & (k units) Table 238. Europe Hypertension Drug Sales Price by Country (2021-2026) & (US$/unit) Table 239. Europe Hypertension Drug Sales Price by Country (2027-2032) & (US$/unit) Table 240. Germany Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 241. France Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 242. U.K. Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 243. Italy Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 244. Russia Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 245. Spain Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 246. Netherlands Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 247. Switzerland Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 248. Sweden Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 249. Poland Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 250. China Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 251. China Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 252. China Hypertension Drug Sales by Type (2021-2026) & (k units) Table 253. China Hypertension Drug Sales by Type (2027-2032) & (k units) Table 254. China Hypertension Drug Sales Price by Type (2021-2026) & (US$/unit) Table 255. China Hypertension Drug Sales Price by Type (2027-2032) & (US$/unit) Table 256. China Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 257. China Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 258. China Hypertension Drug Sales by Application (2021-2026) & (k units) Table 259. China Hypertension Drug Sales by Application (2027-2032) & (k units) Table 260. China Hypertension Drug Sales Price by Application (2021-2026) & (US$/unit) Table 261. China Hypertension Drug Sales Price by Application (2027-2032) & (US$/unit) Table 262. Asia Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 263. Asia Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 264. Asia Hypertension Drug Sales by Type (2021-2026) & (k units) Table 265. Asia Hypertension Drug Sales by Type (2027-2032) & (k units) Table 266. Asia Hypertension Drug Sales Price by Type (2021-2026) & (US$/unit) Table 267. Asia Hypertension Drug Sales Price by Type (2027-2032) & (US$/unit) Table 268. Asia Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 269. Asia Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 270. Asia Hypertension Drug Sales by Application (2021-2026) & (k units) Table 271. Asia Hypertension Drug Sales by Application (2027-2032) & (k units) Table 272. Asia Hypertension Drug Sales Price by Application (2021-2026) & (US$/unit) Table 273. Asia Hypertension Drug Sales Price by Application (2027-2032) & (US$/unit) Table 274. Asia Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 275. Asia Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 276. Asia Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 277. Asia Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 278. Asia Hypertension Drug Sales by Country (2021-2026) & (k units) Table 279. Asia Hypertension Drug Sales by Country (2027-2032) & (k units) Table 280. Asia Hypertension Drug Sales Price by Country (2021-2026) & (US$/unit) Table 281. Asia Hypertension Drug Sales Price by Country (2027-2032) & (US$/unit) Table 282. Japan Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 283. South Korea Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 284. India Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 285. Australia Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 286. Taiwan Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 287. Southeast Asia Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 288. SAMEA Hypertension Drug Revenue by Type (2021-2026) & (US$ Million) Table 289. SAMEA Hypertension Drug Revenue by Type (2027-2032) & (US$ Million) Table 290. SAMEA Hypertension Drug Sales by Type (2021-2026) & (k units) Table 291. SAMEA Hypertension Drug Sales by Type (2027-2032) & (k units) Table 292. SAMEA Hypertension Drug Sales Price by Type (2021-2026) & (US$/unit) Table 293. SAMEA Hypertension Drug Sales Price by Type (2027-2032) & (US$/unit) Table 294. SAMEA Hypertension Drug Revenue by Application (2021-2026) & (US$ Million) Table 295. SAMEA Hypertension Drug Revenue by Application (2027-2032) & (US$ Million) Table 296. SAMEA Hypertension Drug Sales by Application (2021-2026) & (k units) Table 297. SAMEA Hypertension Drug Sales by Application (2027-2032) & (k units) Table 298. SAMEA Hypertension Drug Sales Price by Application (2021-2026) & (US$/unit) Table 299. SAMEA Hypertension Drug Sales Price by Application (2027-2032) & (US$/unit) Table 300. SAMEA Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 301. SAMEA Hypertension Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 302. SAMEA Hypertension Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 303. SAMEA Hypertension Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 304. SAMEA Hypertension Drug Sales by Country (2021-2026) & (k units) Table 305. SAMEA Hypertension Drug Sales by Country (2027-2032) & (k units) Table 306. SAMEA Hypertension Drug Sales Price by Country (2021-2026) & (US$/unit) Table 307. SAMEA Hypertension Drug Sales Price by Country (2027-2032) & (US$/unit) Table 308. Brazil Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 309. Argentina Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 310. Chile Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 311. Colombia Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 312. Peru Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 313. Saudi Arabia Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 314. Israel Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 315. UAE Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 316. Turkey Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 317. Iran Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 318. Egypt Hypertension Drug Revenue (2021-2032) & (US$ Million) Table 319. Key Raw Materials Table 320. Raw Materials Key Suppliers Table 321. Hypertension Drug Distributors List Table 322. Hypertension Drug Customers List Table 323. Research Programs/Design for This Report Table 324. Authors List of This Report Table 325. Secondary Sources Table 326. Primary Sources List of Figures Figure 1. Hypertension Drug Image Figure 2. Global Hypertension Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hypertension Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Beta Blockers Vasodilators Image Figure 5. Alpha Blockers Image Figure 6. Calcium Channel Blockers Image Figure 7. Diuretics Image Figure 8. Renin Inhibitors Image Figure 9. Angiotensin Receptor Blockers Image Figure 10. Angiotensin Converting Enzyme Inhibitors Image Figure 11. Global Hypertension Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hypertension Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Others Image Figure 16. Global Hypertension Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Hypertension Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Hypertension Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Hypertension Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Hypertension Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Hypertension Drug Sales (2021-2032) & (k units) Figure 22. Global Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Hypertension Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Hypertension Drug Sales YoY (2021-2032) & (k units) Figure 25. Europe Hypertension Drug Sales YoY (2021-2032) & (k units) Figure 26. China Hypertension Drug Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Hypertension Drug Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Hypertension Drug Sales YoY (2021-2032) & (k units) Figure 29. Global Hypertension Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Hypertension Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Hypertension Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Hypertension Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Hypertension Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Hypertension Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Hypertension Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Hypertension Drug Sales Market Share by Type (2021-2032) Figure 38. Global Hypertension Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Hypertension Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Hypertension Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Hypertension Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Hypertension Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Hypertension Drug Sales Market Share by Application (2021-2032) Figure 44. North America Hypertension Drug Revenue Share by Type (2021-2032) Figure 45. North America Hypertension Drug Sales Share by Type (2021-2032) Figure 46. North America Hypertension Drug Revenue Share by Application (2021-2032) Figure 47. North America Hypertension Drug Sales Share by Application (2021-2032) Figure 48. North America Hypertension Drug Revenue Share by Country (2021-2032) Figure 49. North America Hypertension Drug Sales Share by Country (2021-2032) Figure 50. Europe Hypertension Drug Revenue Share by Type (2021-2032) Figure 51. Europe Hypertension Drug Sales Share by Type (2021-2032) Figure 52. Europe Hypertension Drug Revenue Share by Application (2021-2032) Figure 53. Europe Hypertension Drug Sales Share by Application (2021-2032) Figure 54. Europe Hypertension Drug Revenue Share by Country (2021-2032) Figure 55. Europe Hypertension Drug Sales Share by Country (2021-2032) Figure 56. China Hypertension Drug Revenue Share by Type (2021-2032) Figure 57. China Hypertension Drug Sales Share by Type (2021-2032) Figure 58. China Hypertension Drug Revenue Share by Application (2021-2032) Figure 59. China Hypertension Drug Sales Share by Application (2021-2032) Figure 60. Asia Hypertension Drug Revenue Share by Type (2021-2032) Figure 61. Asia Hypertension Drug Sales Share by Type (2021-2032) Figure 62. Asia Hypertension Drug Revenue Share by Application (2021-2032) Figure 63. Asia Hypertension Drug Sales Share by Application (2021-2032) Figure 64. Asia Hypertension Drug Revenue Share by Country (2021-2032) Figure 65. Asia Hypertension Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Hypertension Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Hypertension Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Hypertension Drug Revenue Share by Application (2021-2032) Figure 69. SAMEA Hypertension Drug Sales Share by Application (2021-2032) Figure 70. SAMEA Hypertension Drug Revenue Share by Country (2021-2032) Figure 71. SAMEA Hypertension Drug Sales Share by Country (2021-2032) Figure 72. Hypertension Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Hypertension Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers Vasodilators
  • Alpha Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Renin Inhibitors
  • Angiotensin Receptor Blockers
  • Angiotensin Converting Enzyme Inhibitors
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Actelion Ltd.
  • Alvogen
  • Bellerophon Therapeutics, Inc
  • Boehringer Ingelheim
  • Boryung Pharmaceutical Co.,Ltd
  • Bristol-Myers Squibb and Company,
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc
  • HanAll Biopharma Co., Ltd
  • Hanmi Pharmaceutical Co., Ltd
  • JW Pharmaceutical Corporation (Choongwae Pharma)
  • Kyowa Kirin Co., Ltd
  • Lung Biotechnology PBC
  • Lupin Limited
  • Nippon Shinyaku Co. Ltd
  • Noden Pharma DAC
  • Ranbaxy Laboratories Limited
  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc
  • Eli Lilly and Company
  • Merck & Co.
  • Novartis AG
  • Novartis AG
  • Johnson & Johnson Ltd
  • Sanofi S.A

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hypertension Drug Market by Type
  3. 1.2.1 Global Hypertension Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Beta Blockers Vasodilators
  5. 1.2.3 Alpha Blockers
  6. 1.2.4 Calcium Channel Blockers
  7. 1.2.5 Diuretics
  8. 1.2.6 Renin Inhibitors
  9. 1.2.7 Angiotensin Receptor Blockers
  10. 1.2.8 Angiotensin Converting Enzyme Inhibitors
  11. 1.3 Hypertension Drug Market by Application
  12. 1.3.1 Global Hypertension Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Hospitals
  14. 1.3.3 Clinics
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Hypertension Drug Market Dynamics
  1. 2.1 Hypertension Drug Industry Trends
  2. 2.2 Hypertension Drug Industry Drivers
  3. 2.3 Hypertension Drug Industry Opportunities and Challenges
  4. 2.4 Hypertension Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hypertension Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hypertension Drug Revenue by Region
  3. 3.2.1 Global Hypertension Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hypertension Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Hypertension Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Hypertension Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hypertension Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hypertension Drug Sales by Region
  9. 3.4.1 Global Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hypertension Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Hypertension Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Hypertension Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hypertension Drug Revenue by Manufacturers
  2. 4.1.1 Global Hypertension Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hypertension Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hypertension Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hypertension Drug Sales by Manufacturers
  6. 4.2.1 Global Hypertension Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hypertension Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hypertension Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hypertension Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hypertension Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hypertension Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hypertension Drug Manufacturers, Product Type & Application
  13. 4.7 Global Hypertension Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hypertension Drug Market CR5 and HHI
  16. 4.8.2 2025 Hypertension Drug Tier 1, Tier 2, and Tier 3
5 Hypertension Drug Market by Type
  1. 5.1 Global Hypertension Drug Revenue by Type
  2. 5.1.1 Global Hypertension Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hypertension Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hypertension Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hypertension Drug Sales by Type
  6. 5.2.1 Global Hypertension Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hypertension Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Hypertension Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hypertension Drug Price by Type
6 Hypertension Drug Market by Application
  1. 6.1 Global Hypertension Drug Revenue by Application
  2. 6.1.1 Global Hypertension Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hypertension Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hypertension Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hypertension Drug Sales by Application
  6. 6.2.1 Global Hypertension Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hypertension Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Hypertension Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hypertension Drug Price by Application
7 Company Profiles
  1. 7.1 Actelion Ltd.
  2. 7.1.1 Actelion Ltd. Company Information
  3. 7.1.2 Actelion Ltd. Business Overview
  4. 7.1.3 Actelion Ltd. Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Actelion Ltd. Hypertension Drug Product Portfolio
  6. 7.1.5 Actelion Ltd. Recent Developments
  7. 7.2 Alvogen
  8. 7.2.1 Alvogen Company Information
  9. 7.2.2 Alvogen Business Overview
  10. 7.2.3 Alvogen Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Alvogen Hypertension Drug Product Portfolio
  12. 7.2.5 Alvogen Recent Developments
  13. 7.3 Bellerophon Therapeutics, Inc
  14. 7.3.1 Bellerophon Therapeutics, Inc Company Information
  15. 7.3.2 Bellerophon Therapeutics, Inc Business Overview
  16. 7.3.3 Bellerophon Therapeutics, Inc Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Bellerophon Therapeutics, Inc Hypertension Drug Product Portfolio
  18. 7.3.5 Bellerophon Therapeutics, Inc Recent Developments
  19. 7.4 Boehringer Ingelheim
  20. 7.4.1 Boehringer Ingelheim Company Information
  21. 7.4.2 Boehringer Ingelheim Business Overview
  22. 7.4.3 Boehringer Ingelheim Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Boehringer Ingelheim Hypertension Drug Product Portfolio
  24. 7.4.5 Boehringer Ingelheim Recent Developments
  25. 7.5 Boryung Pharmaceutical Co.,Ltd
  26. 7.5.1 Boryung Pharmaceutical Co.,Ltd Company Information
  27. 7.5.2 Boryung Pharmaceutical Co.,Ltd Business Overview
  28. 7.5.3 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product Portfolio
  30. 7.5.5 Boryung Pharmaceutical Co.,Ltd Recent Developments
  31. 7.6 Bristol-Myers Squibb and Company,
  32. 7.6.1 Bristol-Myers Squibb and Company, Company Information
  33. 7.6.2 Bristol-Myers Squibb and Company, Business Overview
  34. 7.6.3 Bristol-Myers Squibb and Company, Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb and Company, Hypertension Drug Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb and Company, Recent Developments
  37. 7.7 Daiichi Sankyo Company
  38. 7.7.1 Daiichi Sankyo Company Company Information
  39. 7.7.2 Daiichi Sankyo Company Business Overview
  40. 7.7.3 Daiichi Sankyo Company Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Daiichi Sankyo Company Hypertension Drug Product Portfolio
  42. 7.7.5 Daiichi Sankyo Company Recent Developments
  43. 7.8 F. Hoffmann-La Roche Ltd.
  44. 7.8.1 F. Hoffmann-La Roche Ltd. Company Information
  45. 7.8.2 F. Hoffmann-La Roche Ltd. Business Overview
  46. 7.8.3 F. Hoffmann-La Roche Ltd. Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 F. Hoffmann-La Roche Ltd. Hypertension Drug Product Portfolio
  48. 7.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
  49. 7.9 Gilead Sciences, Inc
  50. 7.9.1 Gilead Sciences, Inc Company Information
  51. 7.9.2 Gilead Sciences, Inc Business Overview
  52. 7.9.3 Gilead Sciences, Inc Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Gilead Sciences, Inc Hypertension Drug Product Portfolio
  54. 7.9.5 Gilead Sciences, Inc Recent Developments
  55. 7.10 HanAll Biopharma Co., Ltd
  56. 7.10.1 HanAll Biopharma Co., Ltd Company Information
  57. 7.10.2 HanAll Biopharma Co., Ltd Business Overview
  58. 7.10.3 HanAll Biopharma Co., Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 HanAll Biopharma Co., Ltd Hypertension Drug Product Portfolio
  60. 7.10.5 HanAll Biopharma Co., Ltd Recent Developments
  61. 7.11 Hanmi Pharmaceutical Co., Ltd
  62. 7.11.1 Hanmi Pharmaceutical Co., Ltd Company Information
  63. 7.11.2 Hanmi Pharmaceutical Co., Ltd Business Overview
  64. 7.11.3 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product Portfolio
  66. 7.11.5 Hanmi Pharmaceutical Co., Ltd Recent Developments
  67. 7.12 JW Pharmaceutical Corporation (Choongwae Pharma)
  68. 7.12.1 JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
  69. 7.12.2 JW Pharmaceutical Corporation (Choongwae Pharma) Business Overview
  70. 7.12.3 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product Portfolio
  72. 7.12.5 JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments
  73. 7.13 Kyowa Kirin Co., Ltd
  74. 7.13.1 Kyowa Kirin Co., Ltd Company Information
  75. 7.13.2 Kyowa Kirin Co., Ltd Business Overview
  76. 7.13.3 Kyowa Kirin Co., Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Kyowa Kirin Co., Ltd Hypertension Drug Product Portfolio
  78. 7.13.5 Kyowa Kirin Co., Ltd Recent Developments
  79. 7.14 Lung Biotechnology PBC
  80. 7.14.1 Lung Biotechnology PBC Company Information
  81. 7.14.2 Lung Biotechnology PBC Business Overview
  82. 7.14.3 Lung Biotechnology PBC Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Lung Biotechnology PBC Hypertension Drug Product Portfolio
  84. 7.14.5 Lung Biotechnology PBC Recent Developments
  85. 7.15 Lupin Limited
  86. 7.15.1 Lupin Limited Company Information
  87. 7.15.2 Lupin Limited Business Overview
  88. 7.15.3 Lupin Limited Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Lupin Limited Hypertension Drug Product Portfolio
  90. 7.15.5 Lupin Limited Recent Developments
  91. 7.16 Nippon Shinyaku Co. Ltd
  92. 7.16.1 Nippon Shinyaku Co. Ltd Company Information
  93. 7.16.2 Nippon Shinyaku Co. Ltd Business Overview
  94. 7.16.3 Nippon Shinyaku Co. Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Nippon Shinyaku Co. Ltd Hypertension Drug Product Portfolio
  96. 7.16.5 Nippon Shinyaku Co. Ltd Recent Developments
  97. 7.17 Noden Pharma DAC
  98. 7.17.1 Noden Pharma DAC Company Information
  99. 7.17.2 Noden Pharma DAC Business Overview
  100. 7.17.3 Noden Pharma DAC Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Noden Pharma DAC Hypertension Drug Product Portfolio
  102. 7.17.5 Noden Pharma DAC Recent Developments
  103. 7.18 Ranbaxy Laboratories Limited
  104. 7.18.1 Ranbaxy Laboratories Limited Company Information
  105. 7.18.2 Ranbaxy Laboratories Limited Business Overview
  106. 7.18.3 Ranbaxy Laboratories Limited Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Ranbaxy Laboratories Limited Hypertension Drug Product Portfolio
  108. 7.18.5 Ranbaxy Laboratories Limited Recent Developments
  109. 7.19 AstraZeneca Plc
  110. 7.19.1 AstraZeneca Plc Company Information
  111. 7.19.2 AstraZeneca Plc Business Overview
  112. 7.19.3 AstraZeneca Plc Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 AstraZeneca Plc Hypertension Drug Product Portfolio
  114. 7.19.5 AstraZeneca Plc Recent Developments
  115. 7.20 Bayer AG
  116. 7.20.1 Bayer AG Company Information
  117. 7.20.2 Bayer AG Business Overview
  118. 7.20.3 Bayer AG Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Bayer AG Hypertension Drug Product Portfolio
  120. 7.20.5 Bayer AG Recent Developments
  121. 7.21 Pfizer Inc
  122. 7.21.1 Pfizer Inc Company Information
  123. 7.21.2 Pfizer Inc Business Overview
  124. 7.21.3 Pfizer Inc Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Pfizer Inc Hypertension Drug Product Portfolio
  126. 7.21.5 Pfizer Inc Recent Developments
  127. 7.22 Eli Lilly and Company
  128. 7.22.1 Eli Lilly and Company Company Information
  129. 7.22.2 Eli Lilly and Company Business Overview
  130. 7.22.3 Eli Lilly and Company Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Eli Lilly and Company Hypertension Drug Product Portfolio
  132. 7.22.5 Eli Lilly and Company Recent Developments
  133. 7.23 Merck & Co.
  134. 7.23.1 Merck & Co. Company Information
  135. 7.23.2 Merck & Co. Business Overview
  136. 7.23.3 Merck & Co. Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Merck & Co. Hypertension Drug Product Portfolio
  138. 7.23.5 Merck & Co. Recent Developments
  139. 7.24 Novartis AG
  140. 7.24.1 Novartis AG Company Information
  141. 7.24.2 Novartis AG Business Overview
  142. 7.24.3 Novartis AG Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Novartis AG Hypertension Drug Product Portfolio
  144. 7.24.5 Novartis AG Recent Developments
  145. 7.25 Novartis AG
  146. 7.25.1 Novartis AG Company Information
  147. 7.25.2 Novartis AG Business Overview
  148. 7.25.3 Novartis AG Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Novartis AG Hypertension Drug Product Portfolio
  150. 7.25.5 Novartis AG Recent Developments
  151. 7.26 Johnson & Johnson Ltd
  152. 7.26.1 Johnson & Johnson Ltd Company Information
  153. 7.26.2 Johnson & Johnson Ltd Business Overview
  154. 7.26.3 Johnson & Johnson Ltd Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Johnson & Johnson Ltd Hypertension Drug Product Portfolio
  156. 7.26.5 Johnson & Johnson Ltd Recent Developments
  157. 7.27 Sanofi S.A
  158. 7.27.1 Sanofi S.A Company Information
  159. 7.27.2 Sanofi S.A Business Overview
  160. 7.27.3 Sanofi S.A Hypertension Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Sanofi S.A Hypertension Drug Product Portfolio
  162. 7.27.5 Sanofi S.A Recent Developments
8 North America
  1. 8.1 North America Hypertension Drug Market Size by Type
  2. 8.1.1 North America Hypertension Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Hypertension Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Hypertension Drug Price by Type (2021-2032)
  5. 8.2 North America Hypertension Drug Market Size by Application
  6. 8.2.1 North America Hypertension Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Hypertension Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Hypertension Drug Price by Application (2021-2032)
  9. 8.3 North America Hypertension Drug Market Size by Country
  10. 8.3.1 North America Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hypertension Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Hypertension Drug Market Size by Type
  2. 9.1.1 Europe Hypertension Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hypertension Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Hypertension Drug Price by Type (2021-2032)
  5. 9.2 Europe Hypertension Drug Market Size by Application
  6. 9.2.1 Europe Hypertension Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hypertension Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Hypertension Drug Price by Application (2021-2032)
  9. 9.3 Europe Hypertension Drug Market Size by Country
  10. 9.3.1 Europe Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hypertension Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Hypertension Drug Market Size by Type
  2. 10.1.1 China Hypertension Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Hypertension Drug Sales by Type (2021-2032)
  4. 10.1.3 China Hypertension Drug Price by Type (2021-2032)
  5. 10.2 China Hypertension Drug Market Size by Application
  6. 10.2.1 China Hypertension Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Hypertension Drug Sales by Application (2021-2032)
  8. 10.2.3 China Hypertension Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hypertension Drug Market Size by Type
  2. 11.1.1 Asia Hypertension Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hypertension Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Hypertension Drug Price by Type (2021-2032)
  5. 11.2 Asia Hypertension Drug Market Size by Application
  6. 11.2.1 Asia Hypertension Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hypertension Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Hypertension Drug Price by Application (2021-2032)
  9. 11.3 Asia Hypertension Drug Market Size by Country
  10. 11.3.1 Asia Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hypertension Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hypertension Drug Market Size by Type
  2. 12.1.1 SAMEA Hypertension Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hypertension Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hypertension Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Hypertension Drug Market Size by Application
  6. 12.2.1 SAMEA Hypertension Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hypertension Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hypertension Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Hypertension Drug Market Size by Country
  10. 12.3.1 SAMEA Hypertension Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hypertension Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hypertension Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hypertension Drug Value Chain Analysis
  2. 13.1.1 Hypertension Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hypertension Drug Production Mode & Process
  6. 13.2 Hypertension Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hypertension Drug Distributors
  9. 13.2.3 Hypertension Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst